drugset / Trial / NCT04232722
Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation
NaSingle-groupOpen-labelTreatment
Summary
To analyze the safety, efficacy and pharmacokinetic characteristics of sorafenib combined with compound huangdai tablets in patients with recurrent hepatocellular carcinoma after liver transplantation
Timeline
- Start
- 2020-01-01
- Primary completion
- 2021-12-31
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Realgar-Indigo Naturalis Formula | Traditional medicine (herbal / TCM) | 60 mg/kg | Oral |
| Subject | Sorafenib | Small molecule | 200 mg | Oral |